SCHEMBL6883221

SCHEMBL6883221

O=C(c1ccco1)N1CCN(Cc2nc3cccnc3n2Cc2nc3ccccc3[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TSHR P16473 2/20 0.47
LMNA P02545 2/20 0.47
HIF1A Q16665 2/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
TP53 P04637 3/20 0.46
HSD17B10 Q99714 2/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
RECQL P46063 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6881731 0.86 DRD4 (0.52) ALDH1A1LMNAHTTKDM4ETDP1
SCHEMBL6881816 0.85 ALDH1A1 (0.50) ALDH1A1TSHRLMNASMN1; SMN2HTT
SCHEMBL6883746 0.85 DRD4 (0.51) ALDH1A1TSHRLMNAHTTKDM4E
SCHEMBL6878952 0.85 DRD4 (0.51) ALDH1A1HTTKDM4EHPGDDRD4
SCHEMBL6878954 0.82 DRD4 (0.52) ALDH1A1HTTKDM4EHPGDDRD4
SCHEMBL6880280 0.80 HPGD (0.67) ALDH1A1HTTKDM4EHSD17B10HPGD
SCHEMBL6880423 0.79 DRD4 (0.54) ALDH1A1HTTKDM4EHPGDDRD4
SCHEMBL6881533 0.76 DRD4 (0.49) ALDH1A1HTTKDM4EHPGDDRD4
SCHEMBL3398060 0.73 ALDH1A1 (0.77) ALDH1A1MEN1KMT2ATSHRLMNA
SCHEMBL6874013 0.73 DRD4 (0.56) ALDH1A1KDM4EDRD4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040166137-A1 Hetero-substituted benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2004-08-26 US disclosed
WO-2004043913-A2 HETERO-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040166137-A1 Hetero-substituted benzimidazole compounds and antiviral uses thereof MAVS, TIMM13, TIMM10 ALDH1A1 3062/4885MEN1 4683/4885KMT2A 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.